Intellipharmaceutics International Company Profile (NASDAQ:IPCI)

About Intellipharmaceutics International

Intellipharmaceutics International logoIntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals. It has developed several drug delivery systems and a pipeline of products and product candidates in therapeutic areas that include neurology, cardiovascular, gastrointestinal tract, diabetes and pain. The Hypermatrix family of technologies includes IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, IntelliShuttle, Point of Divergence Drug Delivery System (nPODDDS) and Paradoxical OverDose Resistance Activating System (PODRAS). Its products include Focalin XR, Keppra XR, Effexor XR, Protonix, Seroquel XR, Lamictal XR, Pristiq, Oleptro, Coreg CR, OxyContin and Lyrica.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: IPCI
  • CUSIP:
Key Metrics:
  • Previous Close: $2.50
  • 50 Day Moving Average: $2.72
  • 200 Day Moving Average: $2.48
  • 52-Week Range: $29,980,000.00 - $1.41
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 3.66
  • P/E Growth: 0.00
  • Market Cap: $73.45M
  • Outstanding Shares: 29,980,000
  • Beta: 0.92
Profitability:
  • Net Margins: -451.40%
  • Return on Assets: -234.43%
Debt:
  • Current Ratio: 0.94%
  • Quick Ratio: 0.94%
Additional Links:
Companies Related to Intellipharmaceutics International:

Analyst Ratings

Consensus Ratings for Intellipharmaceutics International (NASDAQ:IPCI) (?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $7.33 (199.32% upside)

Analysts' Ratings History for Intellipharmaceutics International (NASDAQ:IPCI)
Show:
DateFirmActionRatingPrice TargetDetails
2/13/2017AegisReiterated RatingBuy$8.00View Rating Details
2/4/2017Maxim GroupSet Price TargetBuy$6.00View Rating Details
10/17/2016Brean CapitalSet Price TargetBuy$8.00View Rating Details
10/13/2015MackieSet Price TargetBuy$12.00View Rating Details
2/24/2015NomuraDowngradeNeutralView Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Intellipharmaceutics International (NASDAQ:IPCI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/13/2016Q216($0.09)($0.08)$1.30 millionViewN/AView Earnings Details
10/9/2015Q315($0.04)($0.08)ViewN/AView Earnings Details
7/13/2015Q215($0.05)($0.06)$1.20 millionViewN/AView Earnings Details
4/14/2015($0.08)($0.04)ViewN/AView Earnings Details
2/23/2015($0.07)($0.06)ViewN/AView Earnings Details
10/15/2014Q3($0.05)($0.07)ViewN/AView Earnings Details
4/14/2014Q114$0.11$0.09$4.49 million$4.70 millionViewN/AView Earnings Details
2/18/2014($0.08)($0.31)ViewN/AView Earnings Details
4/3/2013Q113($0.12)($0.07)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Intellipharmaceutics International (NASDAQ:IPCI)
Current Year EPS Consensus Estimate: $0.11 EPS
Next Year EPS Consensus Estimate: $0.67 EPS

Dividends

Dividend History for Intellipharmaceutics International (NASDAQ:IPCI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Intellipharmaceutics International (NASDAQ:IPCI)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Intellipharmaceutics International (NASDAQ:IPCI)
DateHeadline
News IconIntelliPharmaCeutics International, Inc. (NASDAQ:IPCI) Abuse ... - ABN Newswire (press release) (NASDAQ:IPCI)
www.abnnewswire.net - February 17 at 5:25 PM
News IconStock Check: Reviewing the Numbers for IntelliPharmaCeutics International Inc. (IPCI) - Rives Journal (NASDAQ:IPCI)
rivesjournal.com - February 14 at 5:02 AM
News IconIntellipharmaceutics International Inc. (IPCI) stock slides, “Buy” rating reaffirmed by Aegis Analysts - The Ledger Gazette (NASDAQ:IPCI)
ledgergazette.com - February 14 at 5:02 AM
globenewswire.com logoIntellipharmaceutics Announces 2016 Year End Results - GlobeNewswire (press release) (NASDAQ:IPCI)
globenewswire.com - February 11 at 5:59 PM
investornewswire.com logoIntellipharmaceutics International Inc. (NASDAQ:IPCI) EPS Target Set At $0.21 - Investor Newswire (NASDAQ:IPCI)
www.investornewswire.com - February 10 at 4:58 AM
smarteranalyst.com logoCompany Update (NASDAQ:IPCI): IntelliPharmaCeutics Intl Inc (USA) Announces FDA Acceptance Of Filing Of New ... - Smarter Analyst (NASDAQ:IPCI)
www.smarteranalyst.com - February 3 at 11:32 PM
News IconTechnical Indicator Review on Shares of IntelliPharmaCeutics International Inc. (IPCI) - Sherwood Daily (NASDAQ:IPCI)
sherwooddaily.com - February 3 at 11:32 PM
investopedia.com logoFDA Accepts Intellipharmaceutics Painkiller (IPCI) (NASDAQ:IPCI)
www.investopedia.com - February 3 at 6:30 PM
investopedia.com logoIntellipharmaceutics Painkiller Qualifies for FDA Review (NASDAQ:IPCI)
www.investopedia.com - February 3 at 6:30 PM
streetinsider.com logoIntellipharmaceutics (IPCI) Reports FDA Acceptance for Filing of NDA for Rexista (NASDAQ:IPCI)
www.streetinsider.com - February 3 at 4:42 AM
streetinsider.com logoIntellipharmaceutics (IPCI) Reports FDA Acceptance for Filing of NDA for Rexista - StreetInsider.com (NASDAQ:IPCI)
www.streetinsider.com - February 2 at 11:41 PM
globenewswire.com logoIntellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an ... (NASDAQ:IPCI)
globenewswire.com - February 2 at 6:38 PM
fxpips.com logoThese Stocks Are Gapping Up today, Feb. 2 – SNES, IPCI, SRAX, OSTK, MFIN, SINO, VCEL, DCIX, DRYS, HMNY (NASDAQ:IPCI)
www.fxpips.com - February 2 at 4:43 AM
News IconShares in View: IntelliPharmaCeutics International Inc. (IPCI) - Sherwood Daily (NASDAQ:IPCI)
sherwooddaily.com - January 26 at 2:50 AM
News IconBrokers Release Average Price Target Of 10.85 On Intellipharmaceutics International Inc. (IPCI) - UK Market News (NASDAQ:IPCI)
www.ukmarketnews.co.uk - January 26 at 2:50 AM
News IconSignal Watch: Checking the Numbers for IntelliPharmaCeutics International Inc. (IPCI) - Sherwood Daily (NASDAQ:IPCI)
sherwooddaily.com - January 23 at 11:17 PM
News IconIntellipharmaceutics International Inc. (IPCI) Under Analyst Spotlight - UK Market News (NASDAQ:IPCI)
www.ukmarketnews.co.uk - January 20 at 5:46 AM
News IconCheck on Average Directional Index for IntelliPharmaCeutics International Inc. (IPCI) - Sherwood Daily (NASDAQ:IPCI)
sherwooddaily.com - January 18 at 11:31 PM
News IconEquity Insight: Indicator Review for IntelliPharmaCeutics International Inc. (IPCI) - Sherwood Daily (NASDAQ:IPCI)
sherwooddaily.com - January 17 at 6:06 PM
bizjournals.com logoResearch Reports Coverage on Healthcare Stocks -- Pacira Pharma, Supernus Pharma, Lipocine, and IntelliPharmaCeutics (NASDAQ:IPCI)
www.bizjournals.com - January 12 at 6:27 PM
seekingalpha.com logoIntelliPharmaCeutics Intl (IPCI) Presents At 9th Annual Biotech Showcase 2017 Conference (NASDAQ:IPCI)
seekingalpha.com - January 12 at 6:27 PM
smarteranalyst.com logoCompany Update (NASDAQ:IPCI): IntelliPharmaCeutics Intl Inc (USA) Announces Par Pharmaceutical's Launch of ... - Smarter Analyst (NASDAQ:IPCI)
www.smarteranalyst.com - January 7 at 7:52 PM
News IconIs This a Sensible Stock at Current Levels: IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) - Prospect Journal (NASDAQ:IPCI)
prospectjournal.com - January 5 at 7:17 PM
News IconStock ABR Of Intellipharmaceutics International Inc. (NASDAQ:IPCI) At 1.33 - Stock Observer (NASDAQ:IPCI)
www.thestockobserver.com - January 5 at 7:17 PM
News IconIgniting Curiosity on This Name, Investor Update on IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) - Prospect Journal (NASDAQ:IPCI)
prospectjournal.com - January 5 at 2:47 AM
investornewswire.com logoIntellipharmaceutics International Inc. (NASDAQ:IPCI) Records An Impact Score Of 0 - Investor Newswire (NASDAQ:IPCI)
www.investornewswire.com - January 3 at 4:56 PM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) - Prospect Journal (NASDAQ:IPCI)
prospectjournal.com - January 3 at 11:32 AM
News IconBargain Hunter Investor Update on IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) - Prospect Journal (NASDAQ:IPCI)
prospectjournal.com - December 31 at 5:43 AM
4-traders.com logoIntellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its PODRAS Overdose Technology (NASDAQ:IPCI)
www.4-traders.com - December 22 at 11:14 PM
us.rd.yahoo.com logo8:05 am Intellipharmaceutics Intl announces issuance of patent covering aspects of its Paradoxical OverDose Resistance Activating System delivery technology by the USPTO (NASDAQ:IPCI)
us.rd.yahoo.com - December 22 at 1:55 AM
News IconAre There Any Catalysts to Propel Shares of IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) - Prospect Journal (NASDAQ:IPCI)
prospectjournal.com - December 21 at 6:48 PM
News IconIntellipharmaceutics International (IPCI) receives Valuable PODRAS Patent - CNA Finance (press release) (NASDAQ:IPCI)
cnafinance.com - December 21 at 6:48 PM
globenewswire.com logoIntellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its PODRAS™ Overdose ... - GlobeNewswire (press release) (NASDAQ:IPCI)
globenewswire.com - December 21 at 8:34 AM
publicnow.com logoIntellipharmaceutics Announces Issuance of U.S. and Canadian Patents Covering Aspects of its PODRAS™ Overdose Technology (NASDAQ:IPCI)
www.publicnow.com - December 21 at 8:34 AM
News IconTurning Heads Pre-Bell: IntelliPharmaCeutics International Inc ... - Prospect Journal (NASDAQ:IPCI)
prospectjournal.com - December 17 at 6:17 PM
News IconIntellipharmaceutics International Inc. (NASDAQ:IPCI) Stock ABR At 1.33 - Stock Observer (NASDAQ:IPCI)
www.thestockobserver.com - December 10 at 5:33 PM
investornewswire.com logoBuy Calls Of Intellipharmaceutics International Inc. (NASDAQ:IPCI) At 0 - Investor Newswire (NASDAQ:IPCI)
www.investornewswire.com - December 2 at 5:46 PM
News IconWhere The Shares Price Of Intellipharmaceutics International Inc. (NASDAQ:IPCI) Is Moving? - Stock Observer (NASDAQ:IPCI)
www.thestockobserver.com - December 1 at 6:00 PM
finance.yahoo.com logoIntellipharmaceutics to Present at the LD Micro Main Event (NASDAQ:IPCI)
finance.yahoo.com - November 30 at 6:04 PM
globenewswire.com logoIntellipharmaceutics to Present at the LD Micro Main Event Nasdaq ... - GlobeNewswire (press release) (NASDAQ:IPCI)
globenewswire.com - November 30 at 9:37 AM
News IconInteresting IPCI Put And Call Options For July 2017 (NASDAQ:IPCI)
www.stockoptionschannel.com - November 29 at 4:32 PM
streetinsider.com logoForm 6-K Intellipharmaceutics For: Nov 29 (NASDAQ:IPCI)
www.streetinsider.com - November 29 at 4:32 PM
us.rd.yahoo.com logoIntelliPharmaCeutics Intl Inc (USA) (IPCI) Needs A Partner (NASDAQ:IPCI)
us.rd.yahoo.com - November 29 at 4:32 PM
streetinsider.com logoIntellipharmaceutics (IPCI) Files NDA with FDA for Abuse Deterrent Opioid Analgesic Rexista - StreetInsider.com (NASDAQ:IPCI)
www.streetinsider.com - November 25 at 5:39 PM
News IconWhat are Analysts Expecting for Intellipharmaceutics International Inc. (NASDAQ:IPCI) Earnings? - CSZ News (NASDAQ:IPCI)
cincysportszone.com - November 25 at 5:39 PM
News IconStock Spotter: Review on Technical Levels for IntelliPharmaCeutics International Inc. (IPCI) - Yankee Analysts (NASDAQ:IPCI)
yankeeanalysts.com - November 25 at 5:39 PM
finance.yahoo.com logo7:50 am Intellipharmaceutics Intl submits new drug application for Rexista (NASDAQ:IPCI)
finance.yahoo.com - November 25 at 10:53 AM
News IconStock Strength Review on Shares of IntelliPharmaCeutics International Inc. (IPCI) - MicroCap Wired (NASDAQ:IPCI)
www.microcapwired.com - November 24 at 8:49 AM
News IconPenny Stock Spotlight: Focusing on IntelliPharmaCeutics International Inc. (NASDAQ:IPCI) - Duncan Research (NASDAQ:IPCI)
www.duncanindependent.com - November 23 at 5:43 PM
News IconStock Overview: Moving Average Check on IntelliPharmaCeutics International Inc. (IPCI) - Yankee Analysts (NASDAQ:IPCI)
yankeeanalysts.com - November 22 at 9:36 AM

Social

What is Intellipharmaceutics International's stock symbol?

Intellipharmaceutics International trades on the NASDAQ under the ticker symbol "IPCI."

Where is Intellipharmaceutics International's stock going? Where will Intellipharmaceutics International's stock price be in 2017?

3 brokers have issued twelve-month price objectives for Intellipharmaceutics International's shares. Their forecasts range from $6.00 to $8.00. On average, they expect Intellipharmaceutics International's stock price to reach $7.33 in the next year.

What are analysts saying about Intellipharmaceutics International stock?

Here are some recent quotes from research analysts about Intellipharmaceutics International stock:

  • Aegis analysts commented, "Last Friday, Intellipharmaceutics announced fourth quarter results with top-line revenue of $0.5 mil vs consensus of $0.5 mil and GAAP-eps of $(0.13) vs consensus of $(0.07). The GAAP-eps miss comes on the back of higher than expected R&D expense for the quarter' FY 2016 saw progress. In 2016, Intellipharmaceutics made several key developments: (1) no food effect seen in Rexista, a bio-equivalent to oxycontin; (2) tentative approval for Seroquel XR with a launch planned for 1H17; (2) Partnership agreements for generics Seroquel XR, Pristiq, and Lamictal XR with Mallinckrodt; and (3) Rexista NDA filing. As per the agreement with Mallinckrodt, Intellipharmaceutics received a non-refundable $3 mil in October 2016." (2/13/2017)
  • According to Zacks Investment Research, "Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including neurology, cardiovascular, and GIT. Intellipharmaceutics International Inc. was formerly known as IntelliPharmaCeutics Ltd. and is based in Toronto, Canada. " (1/6/2017)

How do I buy Intellipharmaceutics International stock?

Shares of Intellipharmaceutics International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Intellipharmaceutics International stock cost?

One share of Intellipharmaceutics International stock can currently be purchased for approximately $2.45.

Intellipharmaceutics International (NASDAQ:IPCI) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Intellipharmaceutics International (NASDAQ:IPCI)

Earnings History Chart

Earnings by Quarter for Intellipharmaceutics International (NASDAQ:IPCI)

Dividend History Chart

Dividend Payments by Quarter for Intellipharmaceutics International (NASDAQ:IPCI)

Last Updated on 2/19/2017 by MarketBeat.com Staff